Mosunetuzumab Monotherapy Continues to Demonstrate Durable Responses in Patients With Relapsed and/or Refractory Follicular Lymphoma After=2 Prior Therapies: 3-Year Follow-Up From a Pivotal Phase II Study

被引：0

作者：

Schuster, Stephen J. ^{[1
]}

Sehn, Laurie H. ^{[2
]}

Bartlett, Nancy L. ^{[3
]}

Matasar, Matthew ^{[4
]}

Assouline, Sarit ^{[5
]}

Giri, Pratyush ^{[6
]}

Kuruvilla, John ^{[7
]}

Shadman, Mazyar ^{[8
,9
]}

Cheah, Chan Y. ^{[10
,11
]}

Dietrich, Sascha ^{[12
]}

Fay, Keith ^{[13
,14
]}

Ku, Matthew ^{[15
]}

Nastoupil, Loretta ^{[16
]}

Wei, Michael C. ^{[17
]}

Yin, Shen ^{[17
]}

To, Iris ^{[17
]}

Huang, Jiangeng ^{[17
]}

Kwan, Antonia ^{[17
]}

Penuel, Elicia ^{[17
]}

Budde, L. Elizabeth ^{[18
]}

机构：

[1] Univ Penn, Lymphoma Program, Abramson Canc Ctr, Philadelphia, PA USA

[2] Univ British Columbia, BC Canc Ctr Lymphoid Canc, Vancouver, BC, Canada

[3] Washington Univ, Sch Med, Siteman Canc Ctr, St Louis, MO USA

[4] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA

[5] Jewish Gen Hosp, Montreal, PQ, Canada

[6] Royal Adelaide Hosp, Adelaide, Australia

[7] Princess Margaret Canc Ctr, Toronto, ON, Canada

[8] Fred Hutchinson Canc Res Ctr, Seattle, WA USA

[9] Univ Washington, Seattle, WA USA

[10] Sir Charles Gairdner Hosp, Linear Clin Res, Nedlands, Australia

[11] Univ Western Australia, Perth, Australia

[12] Heidelberg Univ, Heidelberg, Germany

[13] St Vincents Hosp, Sydney, Australia

[14] Royal North Shore Hosp, Sydney, Australia

[15] Univ Melbourne, St Vincents Hosp, Melbourne, Australia

[16] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[17] Genentech Inc, South San Francisco, CA USA

[18] City Hope Natl Med Ctr, Duarte, CA USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷

关键词：

IBCL; non-Hodgkin lymphoma; indolent lymphoma; follicular lymphoma; bispecific antibody;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

IBCL-335

引用

页码：S497 / S497

页数：1

共 50 条

[31] Three-year follow-up analysis of phase 1/2 study on tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma
Yonezawa, Hajime
Narita, Yoshitaka
Nagane, Motoo
Mishima, Kazuhiko
Terui, Yasuhito
Arakawa, Yoshiki
Asai, Katsunori
Fukuhara, Noriko
Sugiyama, Kazuhiko
Shinojima, Naoki
Aoi, Arata
Nishikawa, Ryo
NEURO-ONCOLOGY ADVANCES, 2024, 6 (01)
[32] Glofitamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma: Extended Follow-Up from a Pivotal Phase 2 Study and Subgroup Analyses in Patients with Prior Chimeric Antigen Receptor T-Cell Therapy and by Baseline Total Metabolic Tumor Volume
Hutchings, Martin
Carlo-Stella, Carmelo
Morschhauser, Franck
Falchi, Lorenzo
Bachy, Emmanuel
Cartron, Guillaume
Khan, Cyrus
Tani, Monica
Martinez-Lopez, Joaquin
Bartlett, Nancy L.
Salar, Antonio
Brody, Joshua
Leppa, Sirpa
Baumlin, Pauline
Mulvihill, Estefania
Relf, James
Xie, Yuying
Kaufman, Derrick
Lundberg, Linda
Dickinson, Michael
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S473 - S473
[33] Mosunetuzumab Monotherapy is an effective and well-tolerated Treatment Option in Patients with relapsed/refractory follicular Lymphoma who have previously received plus or minus 2 Lines of Therapy: Key Results from a Phase I/II Study
Hess, G.
Budde, L. E.
Sehn, L. H.
Matasar, M.
Schuster, S. J.
Assouline, S.
Giri, P.
Kuruvilla, J.
Canales, M.
Dietrich, S.
Fay, K.
Ku, M.
Nastoupil, L.
Wei, M. C.
Yin, S.
Doral, M. Y.
Li, C. -C.
Huang, H.
Negricea, R.
Penuel, E.
O'Hear, C.
Bartlett, N. L.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 148 - 148
[34] Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial
Thieblemont, Catherine
Karimi, Yasmin H.
Ghesquieres, Herve
Cheah, Chan Y.
Clausen, Michael Roost
Cunningham, David
Jurczak, Wojciech
Do, Young Rok
Gasiorowski, Robin
Lewis, David John
Kim, Tae Min
van der Poel, Marjolein
Poon, Michelle Limei
Feldman, Tatyana
Linton, Kim M.
Sureda, Anna
Hutchings, Martin
Dinh, Minh H.
Kilavuz, Nurgul
Soong, David
Mark, Thomas
Sacchi, Mariana
Phillips, Tycel
Lugtenburg, Pieternella J.
LEUKEMIA, 2024, : 2653 - 2662
[35] Odronextamab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Grade 1-3a: Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2
Kim, Tae Min
Taszner, Michal
Cho, Seok-Goo
Novelli, Silvana
Le Gouill, Steven
Poon, Michelle Limei
Villasboas, Jose C.
Champion, Rebecca
Bachy, Emmanuel
Guidez, Stephanie
Alonso, Aranzazu Alonso
Jagadeesh, Deepa
Merli, Michele
Tucker, David
Cai, Jingxian
De Oliveira, Carolina Leite
Zhu, Min
Chaudhry, Aafia
Mohamed, Hesham
Ambati, Srikanth R.
Luminari, Stefano
BLOOD, 2022, 140 : 2280 - 2282
[36] Glofitamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and ≥ 2 prior therapies: Pivotal phase II expansion results.
Dickinson, Michael
Carlo-Stella, Carmelo
Morschhauser, Franck
Bachy, Emmanuel
Corradini, Paolo
Iacoboni, Gloria
Khan, Cyrus
Wrobel, Tomasz
Offner, Fritz
Trneny, Marek
Wu, Shang-Ju
Cartron, Guillaume
Hertzberg, Mark
Balari, Anna Sureda
Perez-Callejo, David
Lundberg, Linda
Relf, James
Clark, Emma
Humphrey, Kathryn
Hutchings, Martin
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[37] Phase 1/2 Study of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Results with >4 Years of Follow-up
Furman, Richard R.
Wierda, William G.
Schuh, Anna
Patten, Piers Em
Chaves, Jorge M.
Brown, Jennifer R.
Munir, Talha
Martin, Peter
Awan, Farrukh T.
Stephens, Deborah M.
Ghia, Paolo
Barrientos, Jacqueline C.
Patel, Krish
Woyach, Jennifer A.
Butturini, Anna
de Borja, Marianne
Wang, Min Hui
O'Brien, Susan
Byrd, John C.
BLOOD, 2022, 140 : 9873 - 9875
[38] 3-Year Follow-up Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/ Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)
Neelapu, Sattva S.
Chavez, Julio
Sehgal, Alison R.
Epperla, Narendranath
Ulrickson, Matthew
Bachy, Emanuel
Munshi, Pashna N.
Casulo, Carla
Maloney, David G.
de Vos, Sven
Reshef, Ran
Leslie, Lori A.
Oluwole, Olalekan O.
Yakoub-Agha, Ibrahim
Khanal, Rashmi
Rosenblatt, Joseph D.
Yan, Jiali
Song, Qinghua
Peng, Weixin
Lui, Christine
Wulff, Jacob
Shen, Rhine R.
Poddar, Soumya
Miao, Harry
Beygi, Sara
Jacobson, Caron A.
BLOOD, 2022, 140 : 10380 - 10383
[39] Results of a Second, Prespecified Analysis of the Phase 2 Study ELM-2 Confirm High Rates of Durable Complete Response with Odronextamab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) with Extended Follow-up
Villasboas, Jose. C.
Kim, Tae Min
Taszner, Michal
Novelli, Silvana
Cho, Seok-Goo
Merli, Michele
Ubieto, Ana Jimenez
Tessoulin, Benoit
Poon, Michelle
Walewski, Jan
Yi, Shuhua
Song, Yuqin
Chong, Geoffrey
Luminari, Stefano
Bachy, Emmanuel
Guidez, Stephanie
Alonso, Aranzazu
Jagadeesh, Deepa
Zhang, Wei
Magnano, Laura
Iskierka-Jazdzewska, Elzbieta
Tani, Monica
Cai, Jessica
Uppala, Amulya
Shariff, Saleem
Chi, Lei
Chaudhry, Aafia
Mohamed, Hesham
Ambati, Srikanth
Tucker, David
BLOOD, 2023, 142
[40] A Multicenter Phase II Study of Twice-Weekly Bortezomib plus Rituximab in Patients with Relapsed Follicular Lymphoma: Long-Term Follow-Up
Bari, Alessia
Marcheselli, Raffaella
Marcheselli, Luigi
Alvarez, Isabel
Pozzi, Samantha
Ferri, Paola
Lazzaro, Antonio
Fragasso, Alberto
Neri, Santo
Baldini, Luca
Carella, Angelo Michele
Angrilli, Francesco
Guariglia, Roberto
Buda, Gabriele
Stelitano, Caterina
Sacchi, Stefano
ACTA HAEMATOLOGICA, 2017, 137 (01) : 7 - 14

← 1 2 3 4 5 →